Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Kedzierski

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Parasitology|February 6, 2007
Leishmania vaccines: progress and problemsL Kedzierski, Y Zhu, E Handman
Parasitology|June 4, 2009
Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunityL Kedzierski, J M Curtis, K Kedzierska
Molecular and Biochemical Parasitology|December 29, 1999
Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoeliiL Kedzierski, C G Black, R L Coppel
Infection and Immunity|September 19, 2000
Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challengeL Kedzierski, C G Black, R L Coppel
Infection and Immunity|September 24, 2004
Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strainM W Goschnick, C G Black, L Kedzierski, et al.
Vaccine|June 12, 2003
The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocolA Rainczuk, P M Smooker, L Kedzierski, et al.
Vaccine|September 6, 2001
Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoeliiL Kedzierski, C G Black, A W Stowers, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Parasitology|February 6, 2007
Leishmania vaccines: progress and problemsL Kedzierski, Y Zhu, E Handman
Parasitology|June 4, 2009
Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunityL Kedzierski, J M Curtis, K Kedzierska
Molecular and Biochemical Parasitology|December 29, 1999
Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoeliiL Kedzierski, C G Black, R L Coppel
Infection and Immunity|September 19, 2000
Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challengeL Kedzierski, C G Black, R L Coppel
Infection and Immunity|September 24, 2004
Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strainM W Goschnick, C G Black, L Kedzierski, et al.
Vaccine|June 12, 2003
The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocolA Rainczuk, P M Smooker, L Kedzierski, et al.
Vaccine|September 6, 2001
Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoeliiL Kedzierski, C G Black, A W Stowers, et al.
Pageof 1